Quick View
| Metric | Current Period | Same Period of Previous Year | YoY |
|---|---|---|---|
| Revenue | ¥348.7B | ¥352.0B | −0.9% |
| Operating Income | ¥45.7B | ¥50.0B | −8.6% |
| Ordinary Income | ¥45.8B | ¥50.5B | −9.3% |
| Net Income | ¥33.2B | ¥39.6B | −16.1% |
| ROE | 8.4% | 10.4% | - |
Executive Summary
For the cumulative Q3 of the fiscal year ending March 2026, the Company entered a profit decline phase without revenue growth, as Operating Income and Net Income decreased while Revenue remained almost flat. Revenue was ¥348.7B (-0.9% YoY), Operating Income was ¥45.7B (-8.6%), Ordinary Income was ¥45.8B (-9.3%), and Net Income was ¥33.2B (-16.1%). The primary factors were deteriorating profitability in the core Chemicals Business and extraordinary losses of ¥3.1B, mainly consisting of an impairment loss on investment securities, causing the decline in Net Income to exceed that in Operating Income.
Factors Affecting Results
【Revenue】Revenue was ¥348.7B, a decrease of 0.9% YoY, and remained almost flat. While the core Chemicals Business declined to ¥322.9B (-3.5%), the Equipment Systems Business grew significantly to ¥25.8B (+47.5%), mitigating the overall decline in Revenue. As Chemicals accounts for 92.6% of the revenue mix, demand trends in this business largely determine consolidated Revenue.
【Profit and Loss】Operating Income was ¥45.7B (-8.6%), representing a profit contraction exceeding the decline in Revenue. Segment profit in Chemicals decreased to ¥45.9B (-10.7%, margin 14.2%), indicating deteriorating profitability. Equipment Systems posted a loss of ¥0.3B, compared with a loss exceeding ¥0.5B in the same period of the previous year, and achieved only a reduction in its loss. Ordinary Income was ¥45.8B (-9.3%), with non-operating income and expenses nearly neutral. Profit Before Tax was compressed to ¥42.6B due to extraordinary losses of ¥3.1B, including an impairment loss on investment securities of ¥2.6B. Net Income was ¥33.2B (-16.1%), representing a decline in both Revenue and profit.
Segment Analysis
Chemicals generated Revenue of ¥322.9B (-3.5%), segment profit of ¥45.9B (-10.7%), and a profit margin of 14.2%. It is the core business that generates virtually all of consolidated Operating Income; however, profit contracted more sharply than Revenue, highlighting a significant deterioration in profitability. Equipment Systems expanded substantially, with Revenue of ¥25.8B (+47.5%), but recorded a segment loss of ¥0.3B, leaving profitability improvement as an issue despite higher Revenue. Consolidated results remain highly dependent on Chemicals, making the recovery of demand and profitability in this business the key focus going forward.
Key Financial Metrics
【Profitability】The Operating Income margin was 13.1% and the Net Income margin was 9.5%. Although both declined from the same period of the previous year, they remained relatively favorable levels for a manufacturing company. ROE was 8.4%, consisting of a DuPont decomposition of a Net Income margin of 9.5%, total asset turnover of 0.632x, and financial leverage of 1.39x. The Company is securing profits without increasing financial leverage, although ROE has not reached the favorable level exceeding 10%.【Cash Flow Quality】Accounts receivable were ¥106.7B, accounting for 19.4% of total assets, while DSO was 84 days on an annualized basis, indicating room for improvement in collection efficiency. Inventories were ¥46.0B, accounting for 8.3% of total assets.【Investment Efficiency】Profit Before Tax was ¥42.6B, and the effective tax rate was 22.1%, indicating that the tax burden was not excessive.【Financial Soundness】The Equity Ratio was 71.9% and the current ratio was 270.8%. Cash and deposits of ¥58.6B exceeded interest-bearing debt of ¥29.9B, resulting in a conservative capital structure with a debt-to-equity ratio of 0.39x. Meanwhile, the short-term debt ratio was relatively high at 56.3%, making it an item requiring monitoring.
Cash Flow Analysis
As cash flow statement figures were not included in the disclosed scope, no analysis based on Operating Cash Flow (OCF), investing cash flow, or financing cash flow will be conducted. From a balance sheet perspective, cash and deposits decreased to ¥58.6B from ¥84.1B in the same period of the previous year, while short-term securities increased to ¥95.0B from ¥75.0B in the previous year, suggesting that a portion of funds may have been allocated to securities investments. Accounts receivable increased to ¥106.7B from ¥87.8B in the previous year, and DSO remained at 84 days on an annualized basis, indicating that funds tied up in working capital have become relatively greater even as Operating Income was secured. Retained earnings increased to ¥283.2B from ¥260.3B in the previous year, and equity continued to expand through retained earnings.
Earnings Quality
Operating Income of ¥45.7B was the core source of profit. Non-operating income of ¥1.6B and non-operating expenses of ¥1.6B were almost fully offset, meaning that Ordinary Income of ¥45.8B broadly reflected the Company’s recurring earnings generated by its operations. Meanwhile, extraordinary losses of ¥3.1B, consisting of an impairment loss on investment securities of ¥2.6B and a loss on disposal and sale of fixed assets of ¥0.4B, were temporary factors that reduced Profit Before Tax to ¥42.6B and caused the decline in Net Income to exceed that in Operating Income. The ¥12.5B difference between Ordinary Income of ¥45.8B and Net Income of ¥33.2B was mainly attributable to income taxes of ¥9.4B and the aforementioned extraordinary losses. Comprehensive income was ¥26.7B, below Net Income of ¥33.2B, mainly due to foreign currency translation adjustments of -¥6.4B. Translation differences on overseas assets therefore affected changes in shareholders’ equity.
Earnings Forecast and Guidance
Progress against the full-year forecast was 71.9% for Revenue, 76.2% for Operating Income, 77.5% for Ordinary Income, and 83.0% for Net Income. Profit-related metrics exceeded the standard 75% progress level for the cumulative Q3. The particularly high progress for Net Income suggests that extraordinary losses and the tax burden through the first half remained within expectations. The full-year forecast is Revenue of ¥485.0B (+1.8%) and Operating Income of ¥60.0B (-5.5%), requiring Revenue of ¥136.3B and Operating Income of ¥14.3B in Q4 to achieve the targets. The Company’s forecast full-year Operating Income margin is 12.4%, below the cumulative actual margin of 13.1%, indicating a plan that incorporates a decline in profitability in Q4. There was no revision to the earnings forecast, while only the dividend forecast was revised.
Shareholder Returns
The full-year dividend forecast is ¥75 per share. Based on the full-year Net Income forecast of ¥40.0B and the number of shares outstanding excluding treasury shares, the forecast Payout Ratio is estimated at approximately 31%, a conservative level based on earnings. The actual dividend at the end of Q2 was ¥0, indicating that dividends are expected to be concentrated mainly at the fiscal year-end. The fact that the dividend forecast was revised in the current quarter should be noted as a review based on recent earnings trends. Information regarding share buybacks was not included in the disclosed data.
Risk Factors
-
Deterioration in profitability of the core business (Chemicals): While Revenue declined only 3.5% YoY, segment profit decreased 10.7%, and the profit margin also declined. As this business generates virtually all of consolidated Operating Income, demand and profitability trends will determine overall results.
-
Prolonged collection period for accounts receivable: Accounts receivable were ¥106.7B, accounting for 19.4% of total assets, and DSO was 84 days on an annualized basis. A longer collection period could constrain cash generation even if earnings-based profit is secured.
-
Dependence on short-term debt and possibility of recurring extraordinary losses: The short-term debt ratio was relatively high at 56.3%, creating sensitivity to changes in refinancing conditions. In addition, the Company recorded extraordinary losses of ¥3.1B during the current period, mainly consisting of an impairment loss on investment securities. The recurrence of similar losses could increase volatility in Net Income.
Industry Benchmark (For Reference; Compiled by the Company)
Industry Benchmark (manufacturing)
Profitability and Returns
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Operating Income Margin | 13.1% | 8.6% (4.3%–12.7%) | +4.5pt |
| Net Income Margin | 9.5% | 6.4% (2.8%–10.3%) | +3.1pt |
The Company’s Operating Income margin and Net Income margin both exceed the industry median, placing its profitability relatively high within the industry.
Growth and Capital Efficiency
| Metric | Company | Median (IQR) | Delta |
|---|---|---|---|
| Revenue Growth Rate (YoY) | −0.9% | 3.3% (-2.1%–8.9%) | −4.2pt |
The Revenue growth rate was below the industry median, indicating that top-line growth was relatively weak within the industry.
※Source: Compiled by the Company
Key Points in the Earnings Results
-
Recovery in Revenue and profit in the core Chemicals Business is the most important point for evaluating future results. Segment profit in this business decreased 10.7% YoY, and the structure in which it directly drives consolidated profit remains unchanged.
-
Equipment Systems is on an expansionary trend, with Revenue increasing 47.5% YoY; however, it recorded a segment loss of ¥0.3B. Confirmation of a return to profitability despite higher Revenue will be a key point to monitor.
-
Financial soundness remains strong, with an Equity Ratio of 71.9% and a current ratio of 270.8%. However, DSO of 84 days and a short-term debt ratio of 56.3% warrant attention from a quality perspective, and future working capital management and financing trends will be closely monitored.
This report is an earnings analysis document automatically generated by AI based on XBRL earnings release data. It does not recommend investment in any specific security. The industry benchmarks are reference information compiled by the Company based on publicly disclosed earnings data. Investment decisions should be made at your own discretion and, if necessary, after consulting with a professional advisor.
---End of Report---
AI Financial Analysis
Executive Summary
FY2026 Q3 results were resilient at the gross-profit level but showed earnings compression from higher SG&A and a materially larger extraordinary loss. Revenue declined 0.9% year on year to ¥34.87bn. Operating income declined 8.6% to ¥4.57bn, while ordinary income fell 9.3% to ¥4.58bn. Net income declined more sharply, by 16.0%, to ¥3.32bn. Gross profit was broadly stable at ¥11.73bn, down only 0.3% year on year. The gross margin improved by approximately 22bp to 33.6%, indicating that core production and pricing economics remained relatively firm despite the slight sales decline. However, SG&A increased 5.8% to ¥7.16bn, raising the SG&A-to-sales ratio by about 131bp to 20.5%. Consequently, the operating margin declined by approximately 111bp to 13.1%, though it remains within the good 8-15% profitability range. Chemicals, the core business by operating-income contribution, experienced a 3.5% revenue decline and a 10.7% segment-profit decline. Equipment Systems delivered 47.5% revenue growth and substantially reduced its segment loss, supporting the consolidated result. Net income was additionally burdened by a ¥0.31bn extraordinary loss, principally a ¥0.26bn loss on valuation of investment securities. This explains why the decline in net income exceeded the reduction in operating income. The annualized ROE was 11.2%, supported by a 9.5% net margin and conservative financial leverage of 1.39x. Liquidity remains strong, with a 270.8% current ratio, ¥22.31bn of working capital, and cash plus short-term investment securities of ¥15.36bn. The main balance-sheet concern is not absolute liquidity but the 56.3% short-term debt ratio and elevated 84-day annualized DSO. Management's full-year operating-income forecast of ¥6.00bn is 76.2% achieved at Q3, modestly ahead of the standard 75% pace. Full-year net-income guidance of ¥4.00bn is 83.0% achieved, implying a relatively modest Q4 profit contribution and leaving scope for earnings volatility from non-operating and extraordinary items. The revised ¥75 annual dividend implies a forecast dividend payout ratio of 31.1%, which appears conservative relative to forecast EPS of ¥241.34.
Profitability Analysis
The annualized DuPont ROE is 11.2%, decomposed into a 9.5% net profit margin, 0.843x asset turnover, and 1.39x financial leverage. The company therefore generates returns primarily through healthy margins rather than aggressive balance-sheet leverage. Financial leverage is conservative and is not a material source of ROE risk. The most significant year-on-year earnings change was margin compression below gross profit: gross margin rose to 33.6% from approximately 33.4%, but operating margin declined to 13.1% from approximately 14.2%. This divergence reflects SG&A growth of 5.8% despite a 0.9% revenue decline, causing negative operating leverage. The SG&A ratio rose to 20.5% from approximately 19.2%, a 131bp deterioration. Core Chemicals segment revenue was ¥32.30bn, down 3.5% year on year, and segment profit was ¥4.59bn, down 10.7%; its segment margin fell to 14.2% from 15.4%. Equipment Systems revenue increased to ¥2.58bn from ¥1.75bn, up 47.5%, while its segment loss narrowed to ¥0.03bn from ¥0.15bn; its margin improved to negative 1.2% from negative 8.4%. The Chemicals segment remains the core business, contributing essentially all segment profit, so its margin trajectory is the principal determinant of consolidated earnings. The five-factor analysis shows a 77.9% tax burden and a 93.2% interest burden, both consistent with a manageable tax load and limited financing drag. Interest coverage of 62.87x further confirms that debt servicing does not constrain profitability. The exceptional loss of ¥0.31bn, including ¥0.26bn of investment-security valuation loss, depressed pre-tax and net earnings and should be separated from recurring operating performance. Sustainability of the 13.1% operating margin depends on whether SG&A growth normalizes and whether the Chemicals business can restore volume and segment margins.
Growth Assessment
Top-line growth was weak in FY2026 Q3, with consolidated revenue down 0.9% to ¥34.87bn. The decline was driven by the Chemicals segment, where sales decreased ¥1.16bn year on year to ¥32.30bn. Equipment Systems provided a meaningful offset, increasing sales by ¥0.83bn to ¥2.58bn. The sharp improvement in Equipment Systems loss-making profitability is constructive, but its small absolute profit contribution means it cannot yet offset margin pressure in Chemicals. Gross profit declined only ¥0.04bn, demonstrating relatively stable gross-profit generation despite lower revenue. The larger ¥0.43bn decline in operating income shows that the key constraint is overhead absorption and SG&A discipline rather than a broad gross-margin collapse. The full-year sales forecast is ¥48.50bn, of which 71.9% has been achieved by Q3, 3.1 percentage points below the standard 75% seasonal progress rate. Full-year operating-income guidance is ¥6.00bn, with 76.2% achieved, 1.2 percentage points ahead of the standard pace. Ordinary-income progress is 77.5% against the ¥5.90bn full-year forecast, also ahead of the standard pace. Net-income progress is 83.0% against the ¥4.00bn forecast, suggesting the company expects only ¥0.79bn in Q4 net income. The forecast implies full-year revenue growth of 1.8% but operating-income contraction of 5.5%, indicating that management also anticipates some full-year margin pressure. The revenue outlook therefore relies on a Q4 sales contribution of ¥13.63bn, while profitability delivery depends on preserving the improved gross margin and preventing further SG&A deleveraging.
Financial Health
Financial health is strong overall. The current ratio of 270.8% and quick ratio of 235.6% are well above conventional liquidity thresholds, and working capital totals ¥22.31bn. Current assets of ¥35.36bn exceed current liabilities of ¥13.06bn by a wide margin. Cash and deposits were ¥5.86bn, while short-term investment securities were ¥9.50bn, giving ¥15.36bn of readily deployable financial assets. Interest-bearing debt was ¥2.99bn, equivalent to only 7.5% of total equity; debt/capital was 7.0%. Interest coverage of 62.87x indicates substantial capacity to service financing costs. The balance sheet is equity-funded, with total equity of ¥39.66bn and a capital adequacy ratio of 71.9%. Cash and deposits declined ¥2.55bn year on year, or 30.4%, to ¥5.86bn. This cash reduction was partly offset by a ¥2.00bn increase in short-term investment securities to ¥9.50bn, indicating a shift in the composition of liquid financial assets rather than an equivalent loss of liquidity. Investment securities increased 58.7% year on year to ¥0.12bn, although the absolute balance remains immaterial relative to total assets. PPE accounts for 32.5% of total assets, consistent with a manufacturing-oriented asset base. The ¥0.50bn asset-retirement obligation represents only about 0.3% of total liabilities, indicating limited identified environmental restoration liability relative to the liability base. The refinancing-risk alert requires attention: 56.3% of interest-bearing debt is short-term, above the 40% alert threshold. In absolute terms, the risk is moderated by cash of ¥5.86bn and cash plus short-term investment securities of ¥15.36bn, both substantially exceeding short-term loans of ¥1.69bn. The current portion of long-term loans was reduced to ¥0.51bn from ¥0.91bn, which further improves near-term maturity management.
Notable B/S Changes
Cash and deposits: -¥2.55bn (-30.4%) to ¥5.86bn - cash declined, but ¥2.00bn growth in short-term investment securities to ¥9.50bn partly indicates a reallocation into liquid financial assets rather than a proportionate erosion of liquidity. Investment securities: +¥0.05bn (+58.7%) to ¥0.12bn - the percentage movement is large but the absolute balance is immaterial; the associated ¥0.26bn valuation loss nonetheless shows that securities can create earnings volatility. Finished goods: +¥0.58bn (+14.5%) to ¥4.60bn - growth in finished-goods inventory despite lower consolidated revenue warrants monitoring for demand absorption and potential inventory valuation risk. Property, plant and equipment: -¥0.98bn (-5.2%) to ¥17.91bn - the manufacturing asset base remains substantial at 32.5% of total assets, while construction in progress increased to ¥0.66bn from ¥0.30bn, indicating an ongoing investment pipeline. Total equity: +¥1.66bn (+4.4%) to ¥39.66bn - equity growth and a 71.9% capital adequacy ratio reinforce the company's conservative capital structure.
Cash Flow Quality
Recurring earnings quality is supported by a stable gross-profit base and modest financing burden, but reported net income includes a meaningful non-recurring charge. Extraordinary losses totaled ¥0.31bn, equal to approximately 9.4% of Q3 cumulative net income. The largest component was a ¥0.26bn loss on valuation of investment securities, with a further ¥0.04bn loss on sales and retirement of non-current assets. These items explain part of the gap between ordinary income of ¥4.58bn and net income of ¥3.32bn. The ordinary-income-to-net-income gap is approximately 27%, exceeding 10%, and is mainly attributable to the extraordinary loss and ¥0.94bn income-tax expense. Foreign-exchange gains were ¥0.03bn, or less than 1% of operating income, so foreign exchange was not a material driver of earnings. Working-capital quality requires monitoring because annualized DSO is 84 days, above the 60-day warning threshold. Trade receivables were ¥10.67bn and electronically recorded monetary claims were ¥2.59bn, producing a sizable customer-credit exposure. Trade payables were ¥6.80bn and electronically recorded obligations were ¥0.84bn. Finished-goods inventory was ¥4.60bn, while raw materials were ¥1.55bn and work in process was ¥0.23bn. The inventory composition is weighted toward finished goods, which heightens sensitivity to demand changes, product mix shifts, and inventory valuation risk. The available liquidity buffer of cash and short-term investment securities is ¥15.36bn, providing meaningful balance-sheet capacity to absorb working-capital volatility.
Dividend Sustainability
The full-year dividend forecast is ¥75 per share. Based on forecast EPS of ¥241.34, the forecast dividend payout ratio is approximately 31.1%. This is below the 60% sustainability benchmark and leaves a substantial earnings retention buffer. Q3 cumulative EPS was ¥200.23, already covering the forecast annual dividend by 2.7x. Retained earnings totaled ¥28.32bn, compared with total interest-bearing debt of ¥2.99bn, which supports financial flexibility. Net debt is negative when cash and deposits alone are considered, and the surplus is materially larger when short-term investment securities are included. The dividend revision should be assessed alongside the company's stated forecast rather than the ¥0 Q2 DPS, as the latter is not representative of the forecast annual distribution. The principal factors for dividend durability are Chemicals segment margin recovery, collection discipline given the 84-day DSO, and avoidance of further investment-security valuation losses. The current forecast payout level appears conservative relative to profitability and balance-sheet strength.
Risk Assessment
Business risks include High priority: Chemicals, the core profit contributor, recorded a 3.5% sales decline and a 10.7% segment-profit decline. Its segment margin fell 117bp to 14.2%, making recovery in demand, pricing, or cost absorption central to earnings stability., High priority: Manufacturing demand risk is elevated by the concentration of ¥4.60bn in finished goods inventory. A downturn in customer demand or changes in product mix could pressure inventory turnover, pricing, and valuation., Medium priority: Equipment Systems sales grew 47.5%, but the segment remained loss-making at ¥0.03bn. The segment's turnaround must become sustainably profitable before it can materially diversify consolidated earnings., Medium priority: Chemical manufacturing is exposed to raw-material, energy, environmental-compliance, product-quality, and customer qualification risks. These can affect gross margin even where current gross margin has remained stable., Medium priority: Customer collection risk is elevated by the 84-day annualized DSO, above the 60-day warning level. Slower collections can constrain liquidity conversion and may signal customer-credit or contract-cycle pressure..
Financial risks include Medium priority: The short-term debt ratio is 56.3%, above the 40% refinancing-risk alert threshold. Although liquidity substantially covers short-term loans, a high short-term funding share increases sensitivity to bank-credit conditions and interest-rate changes., Medium priority: Cash and deposits fell 30.4% year on year to ¥5.86bn. The concurrent rise in short-term investment securities moderates this issue, but the composition and liquidity of those investments should be monitored., Low-to-medium priority: A ¥0.26bn loss on valuation of investment securities was the main component of the ¥0.31bn extraordinary loss. Further market-value declines could continue to add volatility below ordinary income., Low priority: Interest expense was ¥0.73bn on a cumulative basis, but interest coverage was a very strong 62.87x and debt/capital was only 7.0%, limiting current solvency risk..
Key concerns include SG&A rose 5.8% while revenue declined 0.9%, producing 111bp operating-margin compression; reversal of this negative operating leverage is the most important near-term earnings variable., The 84-day annualized DSO is a specific quality alert. Its root cause is the large receivables and electronically recorded claims balance relative to sales; its impact is slower cash conversion and greater exposure to customer payment performance., The 56.3% short-term debt ratio is a specific quality alert. Its root cause is the concentration of borrowings in short-dated facilities; its impact is a higher refinancing requirement, although the company's liquid financial assets provide substantial mitigation., Comprehensive income of ¥2.67bn was below net income of ¥3.32bn because of negative other comprehensive income, including foreign-currency translation effects. This indicates some sensitivity of equity to currency translation movements., Full-year sales guidance is only 71.9% achieved at Q3, below the standard 75% progress rate, so Q4 revenue execution is important even though operating-profit guidance is slightly ahead of seasonal progress..
Investment Implications
Key takeaways include Operating profitability remains solid at a 13.1% margin, but the year-on-year trajectory weakened because SG&A growth outpaced revenue., The Chemicals segment is the central earnings driver; its 14.2% segment margin and volume trend are more consequential than the smaller Equipment Systems business., The Equipment Systems segment showed strong sales growth and substantial loss reduction, offering potential upside if it crosses into sustained profitability., Balance-sheet strength is a material stabilizer: capital adequacy is 71.9%, debt/capital is 7.0%, and cash plus short-term investment securities exceed total interest-bearing debt by more than five times., The forecast annual dividend of ¥75 implies a moderate 31.1% payout ratio based on forecast EPS, supported by retained earnings and low leverage., Below-operating-line volatility increased through the ¥0.26bn investment-security valuation loss, which should be distinguished from underlying operating performance..
Metrics to watch include Chemicals segment revenue growth and segment margin, Consolidated SG&A-to-sales ratio and operating margin, Equipment Systems segment profit or loss and margin progression, Annualized DSO, trade receivables, and electronically recorded monetary claims, Finished-goods inventory relative to revenue and demand conditions, Short-term debt ratio, short-term loan balance, and cash plus short-term investment securities, Q4 revenue delivery against the ¥48.50bn full-year forecast, Further losses or gains on investment securities and other extraordinary items.
Regarding relative positioning, The company presents as a conservatively financed Japanese specialty manufacturing/chemical business with good, though moderating, operating profitability. Its annualized ROE of 11.2% is in the good 10-15% range and is achieved without meaningful leverage, differentiating its return profile from debt-supported peers. Relative weakness is concentrated in operating-cost leverage, slower receivable collection, and dependence on the Chemicals segment for profits; relative strength lies in liquidity, low debt, stable gross margin, and a modest dividend payout burden.